Wells Fargo initiated coverage of Omada Health (OMDA) with an Equal Weight rating and $17 price target The company’s cardiometabolic programs are seeing partnership tailwinds but its client concentration and ownership structure “complicate” the competitive dynamics, the analyst tells investors in a research note. Wells sees a balanced risk/reward at current levels.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada announces results from 12-month analysis of GLP-1 companion program
- Omada Health price target lowered to $22 from $29 at Barclays
- Omada Health named Top Pick in Healthcare Technology at Morgan Stanley
- Omada Health’s Strategic Growth and Profitability: A Buy Rating by Craig Hettenbach
- Omada Health Positioned for Growth with Strong Financial Performance and Strategic Market Opportunities